Table 2.

Characteristics of Patients with Abnormal Imaging with or without Subsequent HCC Diagnosis.

	Abnormal Imaging no HCC N=187	Abnormal Imaging with HCC N=69	P value
Baseline Clinical Characteristics
Age, median (IQR)	58.2 (52.2–65.9)	61.1 (55.4–64.6)	0.12
Male Gender, N (%)	105 (56.1%)	47 (68.1%)	0.08
Race, N (%)			0.74
White	162 (90.5%)	57 (87.7%)
Black	8 (4.4%)	4 (6.1%)
Asian	7 (3.9%)	3 (4.6%)
Hispanic/Latino, N (%)	6 (3.2%)	2 (2.9%)	0.90
Etiology of Liver Disease, N (%)			0.76
HCV	75 (40.1%)	33 (47.8%)
Alcoholic cirrhosis	23 (12.3%)	9 (13.0%)
NASH/NAFLD	33 (17.6%)	8 (11.6%)
PBC/PSC	10 (5.4%)	3 (4.3%)
HBV	14 (7.5%)	4 (4.3%)
Other	32 (17.1%)	13 (18.8%)
BMI, median (IQR)	29 (25–35)	30 (25–32)	0.74
Follow-up Duration (yr), median (IQR)	3.28 (1.85–4.18)	1.76 (1.1–2.9)	<0.001
Baseline Labs (median, IQR)
MELD	7 (6–10)	8 (6–11)	0.02
Platelet Count K/μL	103 (75–132)	77 (52–106)	<0.001
Alpha Fetoprotein ng/mL	4 (2.3–7.3)	6.0 (3.5–12.1)	0.003
AST IU/L	55 (39–88)	61 (45–103)	0.07
ALT IU/L	45 (27.5–80)	46 (32–77)	0.88
Total Bilirubin mg/dL	1 (0.7–1.65)	1.3 (0.9–2)	0.02
Alkaline Phosphatase IU/L	111.5 (88–151.5)	140 (95–174)	0.01
Albumin g/dL	3.8 (3.4–4.25)	3.3 (3.1–3.9)	<0.001
INR	1.1 (1.1–1.2)	1.2 (1.1–1.3)	<0.001
Imaging/Diagnostics
Total US, median (IQR; range)	5 (4–8;1–14)	3 (2–5;1–10)	<0.001
Total CT/MRI, median (IQR; range)	2 (1–3; 0–12)	1 (1–3; 1–9)	0.19
Number of nodules on US (IQR)	1 (1–2)	1 (1–3)	0.36
Size of largest nodule on US, cm (IQR)	1.4 (1.1–2.0)	2.3 (1.8–2.8)	<0.001

HCV – hepatitis C, HBV – hepatitis B, PBC – primary biliary cholangitis, PSC – primary sclerosing cholangitis, BMI – Body mass index, MELD – Model of end-stage liver disease; US - ultrasound